PRVs Revisited During Drug Pricing Hearing: FDA Still Doesn’t Like Them
This article was originally published in RPM Report
It’s not what most people will remember from the event, but the Feb. 4 hearing on drug pricing included an exchange reinforcing FDA’s reservations about the priority review voucher program – including a quote from an interview published by The RPM Report.
You may also be interested in...
House bill that would require new clinical studies from sponsor for tropical disease priority review vouchers met with industry concerns about limiting the US agency's flexibility.
The recent series of sales of priority review vouchers at ever-higher prices has transformed what had seemed to be a failed incentive model into a hot topic. However, one key stakeholder is not celebrating the recent developments: the FDA review teams that have to deliver the faster paced reviews continue to have strong reservations about the program.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.